The Importance of Evaluating the Frequency of Thrombotic Events in Patients with Polycythemia Vera JAK2 V617F Positive

The polycythemia vera is a myeloproliferative neoplasia whose overall incidence is 0.7-2.6 cases per 100.000inhabitants a year, what increases with the ages of the patients, independently of sex.PV patients have a higher risk of occurrence of thrombotic events, considering these are the cause of morbidity and mortality of them.The aim of this research was to evaluate the frequency of thrombotic events in patients with polycythemia vera treated in a medical center.We did a molecular analysis of the gene JAK2, evaluating the exons 12 and 14 in samples from 26 patients clinically diagnosed with the disease, in the period of March to September, 2013.As we found, 92.3% of the patients were positive to the mutation JAK2 V617F (exon 14), and 7.7% were negative also to the mutations on the exon 12.The frequency of thrombotic events in these patients was evaluated, describing the main clinical characteristics associated with this mutation.Around 29.16% of the JAK2 V617F positive patients had arterial or venous thrombosis, considering that the venous thrombosis was more frequent.The percentage of patients with the mutation JAK2 V617F, and the frequency of thrombosis in PV JAK2 positive patients demonstrated in our study, is according to the data presented in the literature.With this work, we emphasize the role of the research on this mutation into the causes of thrombotic events, especially in unusual site, pointing the myeloproliferative neoplasia as the cause of thrombophilia.